ES2679819T8 - Composición, método y kit para inhibidor de alfa-1 proteinasa - Google Patents
Composición, método y kit para inhibidor de alfa-1 proteinasaInfo
- Publication number
- ES2679819T8 ES2679819T8 ES10828979T ES10828979T ES2679819T8 ES 2679819 T8 ES2679819 T8 ES 2679819T8 ES 10828979 T ES10828979 T ES 10828979T ES 10828979 T ES10828979 T ES 10828979T ES 2679819 T8 ES2679819 T8 ES 2679819T8
- Authority
- ES
- Spain
- Prior art keywords
- kit
- alpha
- composition
- proteinase inhibitor
- proteinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25771109P | 2009-11-03 | 2009-11-03 | |
| US257711P | 2009-11-03 | ||
| PCT/US2010/055135 WO2011056793A2 (en) | 2009-11-03 | 2010-11-02 | Composition, method, and kit for alpha-1 proteinase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2679819T3 ES2679819T3 (es) | 2018-08-31 |
| ES2679819T8 true ES2679819T8 (es) | 2019-01-22 |
Family
ID=43970713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10828979.4T Active ES2679819T3 (es) | 2009-11-03 | 2010-11-02 | Composición, método y kit para inhibidor de alfa-1 proteinasa |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20130131192A1 (es) |
| EP (1) | EP2496246B1 (es) |
| JP (2) | JP2013510158A (es) |
| KR (1) | KR20120114235A (es) |
| CN (1) | CN102655876B (es) |
| AU (1) | AU2010315325B2 (es) |
| BR (1) | BR112012010392B8 (es) |
| CA (1) | CA2779369C (es) |
| CL (1) | CL2012001159A1 (es) |
| ES (1) | ES2679819T3 (es) |
| HU (1) | HUE039240T2 (es) |
| IL (1) | IL219485A (es) |
| MX (1) | MX2012005132A (es) |
| NZ (1) | NZ599783A (es) |
| PL (1) | PL2496246T3 (es) |
| PT (1) | PT2496246T (es) |
| RU (1) | RU2555332C2 (es) |
| TR (1) | TR201809898T4 (es) |
| WO (1) | WO2011056793A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013098672A2 (en) * | 2011-12-30 | 2013-07-04 | Grifols, S.A. | Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations |
| EP3565584A4 (en) * | 2016-12-22 | 2021-01-06 | Kamada Ltd. | DRY POWDER FORMULATIONS OF ALPHA-1-ANTITRYPSINE |
| WO2018132874A1 (en) * | 2017-01-19 | 2018-07-26 | Csl Limited | Method of preventing an immune response with alpha- 1 anti-trypsin |
| IL267923B2 (en) * | 2018-08-02 | 2023-06-01 | Grifols Worldwide Operations Ltd | The composition containing the most concentrated alpha-1 type protein inhibitor and a method for obtaining it |
| JP7545987B2 (ja) * | 2019-03-04 | 2024-09-05 | ティーエーイー ライフ サイエンシーズ | ホウ素中性子捕捉療法において使用するためのボリル化されたアミノ酸組成物およびその方法 |
| EP4110808A1 (en) | 2020-02-25 | 2023-01-04 | Grifols Worldwide Operations Limited | Method for obtaining alpha-1 proteinase inhibitor |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5029005B2 (es) * | 1972-05-08 | 1975-09-19 | ||
| JPS51118819A (en) * | 1975-04-08 | 1976-10-19 | Green Cross Corp:The | A process for preparing heat stable antitrypsin |
| JPS597693B2 (ja) | 1978-01-07 | 1984-02-20 | 株式会社ミドリ十字 | 抗トロンビン製剤及びその製法 |
| US4337242A (en) | 1980-02-05 | 1982-06-29 | Merck & Co., Inc. | Vaccine stabilizer containing L-glutamic acid and L-arginine |
| US4623717A (en) * | 1980-03-05 | 1986-11-18 | Miles Laboratories, Inc. | Pasteurized therapeutically active protein compositions |
| EP0082481B2 (en) | 1981-12-23 | 1990-09-12 | Schering Corporation | Stabilised alpha-interferon formulations and their preparation |
| US4517294A (en) | 1982-03-03 | 1985-05-14 | Genentech, Inc. | Human antithrombin III |
| US4632981A (en) | 1982-07-30 | 1986-12-30 | Genentech, Inc. | Human antithrombin III |
| US5218091A (en) | 1982-08-13 | 1993-06-08 | Zymogenetics, Inc. | Glycolytic promoters for regulated protein expression: protease inhibitor |
| US4711848A (en) | 1984-03-14 | 1987-12-08 | Zymogenetics, Inc. | Site specific mutagenesis in alpha-1-antitrypsin |
| US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
| US4732973A (en) | 1984-06-14 | 1988-03-22 | Chiron Corporation | Active site modified protease α-1-antitrypsin inhibitors |
| DE3581328D1 (de) | 1984-06-19 | 1991-02-21 | Transgene Sa | Derivate des menschlichen alpha-1-antitrypins und verfahren zu deren herstellung. |
| US5366894A (en) | 1986-06-30 | 1994-11-22 | Pharmaceutical Proteins Limited | Peptide production |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| DE3901917A1 (de) | 1989-01-24 | 1990-07-26 | Behringwerke Ag | Mutanten von humanem antithrombin iii |
| GB8913183D0 (en) | 1989-06-08 | 1989-07-26 | Central Blood Lab Authority | Chemical products |
| US5079336A (en) | 1989-06-23 | 1992-01-07 | The Trustees Of The University Of Pennsylvania | α-1-antichymotrypsin, analogues and methods of production |
| US5032405A (en) | 1989-09-27 | 1991-07-16 | Warner-Lambert Company | Oral pharmaceutical composition for acid sensitive proteinaceous agents |
| US5134119A (en) | 1990-10-16 | 1992-07-28 | Lezdey John | Treatment of inflammation using 358 substituted alpha-antitrypsin |
| JP3479539B2 (ja) | 1992-04-10 | 2003-12-15 | エーザイ株式会社 | ヒトアンチトロンビンｉｉｉ変異体 |
| US6051256A (en) * | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| FR2719479B1 (fr) * | 1994-05-04 | 1996-07-26 | Sanofi Elf | Formulation stable lyophilisée comprenant une protéine: kit de dosage. |
| US5561115A (en) | 1994-08-10 | 1996-10-01 | Bayer Corporation | Low temperature albumin fractionation using sodium caprylate as a partitioning agent |
| US5843705A (en) | 1995-02-21 | 1998-12-01 | Genzyme Transgenic Corporation | Transgenically produced antithrombin III |
| AT407114B (de) | 1997-06-10 | 2000-12-27 | Immuno Ag | Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung |
| CA2328397A1 (en) | 1998-05-12 | 1999-11-18 | Temple University - Of The Commonwealth System Of Higher Education | Human antithrombin iiis and methods related thereto |
| JP5149470B2 (ja) | 1999-02-22 | 2013-02-20 | バクスター・インターナショナル・インコーポレイテッド | 新規のアルブミンを含有していない第ｖｉｉｉ因子処方物 |
| WO2000051624A2 (en) * | 1999-03-05 | 2000-09-08 | The Trustees Of University Technology Corporation | Methods and compositions useful in inhibiting apoptosis |
| US20040157911A1 (en) | 1999-08-31 | 2004-08-12 | Spiridon Spireas | Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof |
| DE10022092A1 (de) * | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
| EP1298217A4 (en) | 2000-07-05 | 2004-09-08 | Mitsubishi Pharma Corp | GLYCOPROTEIN PRODUCTION PROCESS |
| AU2002335046A1 (en) * | 2001-10-19 | 2003-05-06 | Inhale Therapeutic Systems, Inc. | The use of proton sequestering agents in drug formulations |
| WO2003086451A1 (en) | 2002-04-05 | 2003-10-23 | Centocor, Inc. | Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses |
| CN1838964A (zh) * | 2002-04-25 | 2006-09-27 | 斯克里普斯研究学院 | 肺病的治疗与预防 |
| US7777006B2 (en) * | 2002-12-31 | 2010-08-17 | Csl Behring L.L.C. | Method for purification of alpha-1-antitrypsin |
| ES2305845T5 (es) | 2003-09-22 | 2012-04-12 | Kamada Ltd. | Preparación a gran escala de un inhibidor de proteinasa alfa-1 y su utilización |
| US7691810B2 (en) | 2003-10-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Method of producing recombinant antithrombin III composition |
| DK1684719T3 (da) * | 2003-11-14 | 2012-01-30 | Baxter Int | Alfa-1-antitrypsin-sammensætninger og behandlingsfremgangsmåder, der anvender sådanne sammensætninger |
| WO2005049801A2 (en) | 2003-11-14 | 2005-06-02 | Arriva Pharmaceuticals, Inc. | Dry protein formulation |
| JP2007526329A (ja) | 2004-03-04 | 2007-09-13 | ワイス | 賦形剤の結晶化を改善するための凍結乾燥法 |
| US20070105768A1 (en) * | 2004-11-10 | 2007-05-10 | Rajiv Nayar | Dry recombinant human alpha 1-antitrypsin formulation |
| RU2008118166A (ru) | 2005-11-22 | 2009-12-27 | Вайет (Us) | Составы, содержащие гибридные белки, включающие иммуноглобулин |
| CA2641875C (en) | 2006-02-09 | 2016-10-04 | Kamada Ltd. | Pulmonary delivery of alpha-1 proteinase inhibitor |
| JP5810091B2 (ja) | 2009-11-24 | 2015-11-11 | グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 凍結乾燥方法、組成物、及びキット |
-
2010
- 2010-11-02 EP EP10828979.4A patent/EP2496246B1/en not_active Revoked
- 2010-11-02 TR TR2018/09898T patent/TR201809898T4/tr unknown
- 2010-11-02 RU RU2012122793/15A patent/RU2555332C2/ru active
- 2010-11-02 ES ES10828979.4T patent/ES2679819T3/es active Active
- 2010-11-02 HU HUE10828979A patent/HUE039240T2/hu unknown
- 2010-11-02 US US13/504,783 patent/US20130131192A1/en not_active Abandoned
- 2010-11-02 NZ NZ599783A patent/NZ599783A/xx unknown
- 2010-11-02 AU AU2010315325A patent/AU2010315325B2/en active Active
- 2010-11-02 WO PCT/US2010/055135 patent/WO2011056793A2/en active Application Filing
- 2010-11-02 BR BR112012010392A patent/BR112012010392B8/pt active IP Right Grant
- 2010-11-02 CA CA2779369A patent/CA2779369C/en active Active
- 2010-11-02 JP JP2012537945A patent/JP2013510158A/ja not_active Withdrawn
- 2010-11-02 PL PL10828979T patent/PL2496246T3/pl unknown
- 2010-11-02 MX MX2012005132A patent/MX2012005132A/es active IP Right Grant
- 2010-11-02 CN CN201080054535.7A patent/CN102655876B/zh active Active
- 2010-11-02 PT PT108289794T patent/PT2496246T/pt unknown
- 2010-11-02 KR KR1020127013706A patent/KR20120114235A/ko active Search and Examination
-
2012
- 2012-04-30 IL IL219485A patent/IL219485A/en active IP Right Grant
- 2012-05-03 CL CL2012001159A patent/CL2012001159A1/es unknown
-
2015
- 2015-09-04 JP JP2015175001A patent/JP6030201B2/ja active Active
- 2015-10-29 US US14/926,450 patent/US9616126B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0919575A2 (pt) | método, e, composição | |
| EP2239261A4 (en) | PYRROLOPYRIMIDINE DERIVATIVE FOR USE AS A PI3K INHIBITOR AND USE THEREOF | |
| BRPI0809573A8 (pt) | composição, e, método | |
| ZA201100147B (en) | Method of preparing alpha-1 proteinase inhibitor | |
| BRPI0915984A2 (pt) | método para inibição da corrosão | |
| BRPI1014974A2 (pt) | ferramenta de válvula para poço e método de utilização | |
| BRPI0812139A2 (pt) | Método para remoção de odor de vinagre | |
| BRPI1008326A2 (pt) | Composições e métodos para controlar nanatódeos | |
| BRPI0823277A2 (pt) | Composição, e , método | |
| EP2243809A4 (en) | ALLERGENINHIBITOR, ALLERGENIC AGENT, ALLERGENIC PROCEDURE, AND USE AS ALLERGENINHIBITOR | |
| HK1218658A1 (zh) | 蛋白酶 抑制劑及其方法和組合物 | |
| BRPI1006861A2 (pt) | métodos para isolar bactérias | |
| BRPI0909924A2 (pt) | ferramenta e método para remoção de implante | |
| BRPI0814167A2 (pt) | Composição, e, método | |
| BR112012001967A2 (pt) | micro-organismo, e, método e composição para suprimir a fusariose em uma planta de cereal | |
| BRPI0823238A2 (pt) | Composição, e, método | |
| BRPI1006996A2 (pt) | composição, método e uso | |
| ES2679819T8 (es) | Composición, método y kit para inhibidor de alfa-1 proteinasa | |
| FR2950804B1 (fr) | Composition, utilisation et procede de conservation | |
| BRPI1014087A2 (pt) | método aperfeiçoado para preparar inibidor de dipeptidil dipeptidase-iv e intermediário | |
| ZA201102179B (en) | Protease inhibitors | |
| BRPI0919136A2 (pt) | Método para conservação de bebidas | |
| BRPI0913397A2 (pt) | Composição, método e kit para preparar plasmina | |
| BRPI0822856A2 (pt) | Composição, e, método | |
| EP2272521A4 (en) | INHIBITOR OF KETONE ACCUMULATION |